Onkologie. 2017:11(1):11-13 | DOI: 10.36290/xon.2017.003
Sunitib in adjuvant treatment for renal cell carcinoma
- Onkologická klinika, 2. LF UK, Fakultní nemocnice Motol, Praha
Despite the extensive possibilities of systemic treatment for advanced renal cell carcinoma have been still missing positive adjuvant
trials. Several studies with immunotherapy based on interferon alfa or interleukin -2 failed. The adjuvant trials with TKI concluded
with conflicting results. The ASSURE study compared sunitinib or sorafenib with placebo was not able to detect any difference in
diseases free survival compared to placebo and was associated with high rate of toxicity and discontinuation of treatment. The
adjuvant trial S-TRAC comparing sunitinib and placebo resulted in prolonged diseases free survival 6.8 years vs. 5.6 years. None
of these trials incorporated a new validated genetic recurrence score to predict the risk of recurrence. The adjuvant systemic
treatment for renal cell carcinoma is not recommended in the clinical daily practise today.
Keywords: renal cell carcinoma, adjuvant treatment, sunitinib, sorafenib
Published: February 1, 2017 Show citation
References
- Pizzocaro G, Piva L, Colavita M, et al. Interferon adjuvant to radical nephrectomy in Robson stage II and III renal cell carcinoma:A multicentric randomized study. J Clin Oncol. 2001; 19 (2): 425-431.
Go to original source... 
Go to PubMed... - Messing EM, Manola J, Wilding G, et al. Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: An Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol. 2003; 21(7): 1214-1222. Go to original source... Go to PubMed...
- Clark JL, Atkins MB, Urba WJ, et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma. A cytokine working group randomized trial. J Clin Oncol. 2003; 21(16): 3133-3140. Go to original source... Go to PubMed...
- Haas NB, Manola J, Uzzo RG, et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOIG-ACRIN E2805): double blind, placebo controlled, randomized, phase 3 trial. Lancet. 2016; 387(10032): 2008-2016. Go to original source... Go to PubMed...
- EU Clinical Trials Register [online]. London: European Medicines Agency [cit. 2017-2-2]. Dostupné z: https://www.clinicaltrialsregister.eu/ctr
- Rini B, Goddard A, Knezevic D, et al. A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies. Lancet. 2015; 16(6): 676-685. Go to original source... Go to PubMed...
- Kapur P, Pena-Llopis S, Christie A, et al. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: restrospective analysis with independent validation. Lancet-Oncol. 2013; 14: 159-167. Go to original source... Go to PubMed...